Frontiers in Immunology (Jun 2022)

Harnessing the B Cell Response in Kidney Transplantation – Current State and Future Directions

  • Imran J. Anwar,
  • Isabel F. DeLaura,
  • Qimeng Gao,
  • Joseph Ladowski,
  • Annette M. Jackson,
  • Jean Kwun,
  • Stuart J. Knechtle

DOI
https://doi.org/10.3389/fimmu.2022.903068
Journal volume & issue
Vol. 13

Abstract

Read online

Despite dramatic improvement in kidney transplantation outcomes over the last decades due to advent of modern immunosuppressive agents, long-term outcomes remain poor. Antibody-mediated rejection (ABMR), a B cell driven process, accounts for the majority of chronic graft failures. There are currently no FDA-approved regimens for ABMR; however, several clinical trials are currently on-going. In this review, we present current mechanisms of B cell response in kidney transplantation, the clinical impact of sensitization and ABMR, the B cell response under current immunosuppressive regimens, and ongoing clinical trials for ABMR and desensitization treatment.

Keywords